Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04214262 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 598 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Results posted: Oct 6, 2026 Secondary endpoints: details revised at 3 of 4 entries · Site details revised at 24 of 391 sites Show 2 more changesShow less
    • Secondary endpoints: details revised at 3 of 4 entries
    • Site details revised at 24 of 391 sites
  2. Enrollment target: 415 to 417v597
  3. Primary completion moved earlier from May 1, 2028 to Aug 24, 2024 Enrollment reduced: 480 → 415 participants · Completion moved earlier from May 1, 2028 to Jun 9, 2027v596 Show 2 more changesShow less
    • Enrollment reduced: 480 → 415 participants
    • Completion moved earlier from May 1, 2028 to Jun 9, 2027
  4. 2 versions Re-verified since May 2, 2026, no change to tracked fieldsv594-v595
  5. Study Status, Contacts/Locationsv593
  6. 44 versions Re-verified since Feb 6, 2026, no change to tracked fieldsv549-v592
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase III trial studies how well atezolizumab added to the usual radiation therapy works in treating patients with stage I-IIA non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy, such as stereotactic body radiation therapy, uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Giving atezolizumab and radiation therapy may work better than radiation therapy alone in treating patients with early non-small cell lung cancer.
Trial Details
NCT Number NCT04214262
Lead Sponsor National Cancer Institute (NCI)
Conditions Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8
Enrollment 417 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov